Cencora, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a COR research report →
Range $330 – $400
Price Chart
About the company
Cencora, Inc. functions as a global leader in the sourcing and distribution of pharmaceutical products, with operations spanning both the United States and international markets. Within its U.
- CEO
- Robert Mauch
- IPO
- 1995
- Employees
- 49,000
- HQ
- Conshohocken, PA, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a strong multi-month uptrend, holding well above its 200-day average and near the upper end of its 52-week range. That keeps the regime constructive, with pullbacks still looking like trend tests rather than a broken setup.
Street sentiment stays favorable: the consensus is Buy, with an average target of 364 versus a last close of 348.31. Recent action is mixed but constructive, with Wells Fargo lifting its target to 400 while keeping an Overweight view and several other firms nudging targets higher.
Cencora has a clean beat streak, going 8-for-8 on EPS surprises, including a 2.2% beat in the latest quarter. Next-year EPS is still trending higher to 19.7643, so shareholders should watch whether management can keep margin discipline while revenue growth stays steady.
No notable discretionary insider buying or selling. The recent filings are dominated by award, exempt, and in-kind transactions tied to executive compensation and vesting, which read as routine rather than a directional signal.
Profitability is modest but stable for a distributor: net margin is 1.03% and operating margin is 1.39%, while revenue grew 5.5% and earnings grew 11.9% year over year. Free cash flow remains strong at $5.70 billion, but net debt is still negative at $6.39 billion.
Cencora’s edge is scale and consistency in pharmaceutical distribution, where its cash generation and earnings reliability stand out. The valuation is not cheap, but it still trades below the average analyst target and near the middle of the recent target range.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $64.71B
- P/E
- 18.85
- Fwd P/E
- 17.27
- PEG
- 0.15
- P/S
- 0.19
- P/B
- 17.58
- EV/EBITDA
- 11.55
- Div Yield
- 0.73%
- Gross Margin
- 3.95%
- Op Margin
- 1.30%
- Net Margin
- 1.03%
- ROE
- 115.76%
- ROIC
- 13.46%
Latest fiscal year · YoY change
- Revenue
- $337.40B+5.0%
- Gross Profit
- $13.87B+36.7%
- Op Income
- $3.93B
- Net Income
- $3.48B+124.2%
- EPS
- $18.03+124.8%
- OCF Growth
- +23.6%
- FCF Growth
- +21.0%
- 52W High
- $377.54
- 52W Low
- $244.82
- 50D MA
- $329.11
- 200D MA
- $316.63
- Beta
- 0.58
- RSI (14)
- 49
- Avg Volume
- 1.29M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Cencora posted record fiscal 26 results, sharpened its specialty-focused operating model, and guided fiscal 27 EPS and operating income growth ahead of long-term targets excluding portfolio changes.· November 4, 2026
- Fiscal 26 adjusted operating income rose 14% and adjusted diluted EPS rose 12% to $17.97, with another record year of results.
- Q4 revenue was $88.4 billion, up 6%; adjusted gross profit was $3.6 billion, up 23%; adjusted operating income was $1.2 billion, up 22%; adjusted EPS was $4.66, up 21%.
- Management resegmented the company into Specialty Pharmaceutical and Provider Services and Pharmaceutical Distribution and Services to better align leadership, customer focus, and investor visibility.
- Fiscal 27 guidance calls for adjusted EPS of $19.40 to $19.75, revenue growth of 3% to 5%, and operating income growth of 4% to 6%; excluding businesses and other, operating income growth would be 8.5% to 11%.
- The company raised its quarterly dividend by 10% and expects about $1.25 billion of additional share repurchases in fiscal 27, while also targeting $1 billion of capital spending and about $3.5 billion of adjusted free cash flow.
Fourth quarter consolidated revenue was $88.4 billion, up 6% year over year. Consolidated adjusted gross profit was $3.6 billion, up 23%, and adjusted gross margin expanded 57 basis points to 4.04%. Consolidated adjusted operating expenses were $2.3 billion, up 23%; adjusted operating income was $1.2 billion, up 22%; net interest expense was $136 million; the tax rate was 20.2%; diluted share count was 191.7 million; and adjusted diluted EPS was $4.66, up 21%. For the full fiscal year, revenue was $337 billion, up 5%; operating income was $4.8 billion, up 14%; and adjusted diluted EPS was $17.97, up 12%. Free cash flow was $3.8 billion, cash ended at $4.9 billion, and the company returned $1.5 billion to shareholders. For fiscal 27, management guided to adjusted EPS of $19.40 to $19.75, revenue growth of 3% to 5%, operating income growth of 4% to 6%, interest expense of $490 million to $510 million, an effective tax rate of about 20%, diluted shares of about 190 million, capital expenditures of $1 billion, and adjusted free cash flow of about $3.5 billion. They also said first-quarter adjusted EPS should be about $4.55. Segment guidance: Pharmaceutical Distribution and Services revenue growth of 4% to 6% and operating income growth of 2% to 4%; Specialty Pharmaceutical and Provider Services revenue growth of 9% to 14% and operating income growth of 18% to 21%; Other revenue of about $3.5 billion and operating income of about $200 million.
Robert Mauch framed the year as one of strategic refinement and stronger focus on specialty, saying Cencora’s portfolio is increasingly aligned to areas where it can create the most long-term value. He emphasized that specialty biologics are a fast-growing market and pointed to the company’s MSO platform, clinical trial capabilities, and global logistics footprint as evidence of the strategy in action. His tone was confident and constructive, stressing that the new operating model should improve execution, customer proximity, and visibility for shareholders.
Eva Boratto focused on the numbers, noting consolidated Q4 revenue of $88.4 billion, adjusted gross profit of $3.6 billion, and adjusted EPS of $4.66, with margin expansion to 4.04% and operating income up 22%. For the full year, she highlighted $3.8 billion of adjusted free cash flow, $4.9 billion of cash, and $1.5 billion returned to shareholders, while also pointing to a 10% dividend increase and planned $1.25 billion of repurchases in fiscal 27. She explained that fiscal 27 guidance reflects the impacts of the MWI/Covetrus merger, the ProPharma divestiture, higher interest expense from OneOncology-related debt, and about $1 billion of capex tied to supply chain, digital, SAP, and MSO investments.
Analysts focused on why Cencora resegmented now, how much of specialty growth is organic versus acquisition-driven, and whether reimbursement, biosimilars, generics, and customer concentration could affect the outlook. Management said the new structure reflects the market’s rapid specialty growth and consolidates previously scattered assets under one leader to improve execution and customer service. On specialty, Eva said the 18% to 21% segment operating income growth outlook is above the long-term algorithm largely because of the OneOncology wraparound, while Bob said biosimilars and generics are contemplated in guidance and are generally positive for Cencora, especially Part B biosimilars. When asked about customer and competitive risks like Option Care or other distribution shifts, Eva said such effects are contemplated within guidance ranges and Bob said they would not comment further on individual customer relationships.
The bullish case is that Cencora is showing strong operating momentum while deliberately refocusing the portfolio on higher-growth, higher-margin specialty businesses. Management repeatedly cited specialty as a major long-term driver, with record results in fiscal 26, segment operating income growth ahead of the company’s long-term algorithm, and continued investment in MSOs, logistics, and provider services. The company also backed that optimism with a dividend increase, buybacks, and guidance that implies growth still above its long-term targets excluding portfolio noise.
The main risks are the expected drag from portfolio changes, higher interest expense, and customer- or product-mix volatility. Management said fiscal 27 growth will be held back by the ProPharma sale, the assumed midyear MWI/Covetrus merger, a customer volume shift, and about $20 million of FX headwind in the distribution segment. Analysts also pressed on reimbursement, biosimilar conversion dynamics, and possible customer losses, and management acknowledged those are monitored closely even if they believe the impacts are largely already embedded in guidance.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.4%
- Shares Outstanding
- 190.83M
- Float Shares
- 180.21M
of shares held by institutions
1,395 13F filers
Buy/sell ratio 0.95. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for COR, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Ro KhannaHouse · CA17 | Sell | Oct 7, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 4, 26 | Filing → |
| Alan ArmstrongSenate | Buy | Mar 27, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Sell | May 6, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Sell | May 6, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Mar 23, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Mar 31, 26 | Filing → |
| Jared MoskowitzHouse · FL23 | Buy | Mar 23, 26 | Filing → |
| Jefferson ShreveHouse · IN06 | Sell | May 12, 25 | Filing → |
| Greg LandsmanHouse · OH01 | Sell | Mar 27, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Nov 15, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Oct 9, 24 | Filing → |
| Michael T. McCaulHouse · TX10 | Buy | Oct 9, 24 | Filing → |
| Greg LandsmanHouse · OH01 | Buy | May 29, 24 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 23.62M | ▲ 221.57K |
| Blackrock, Inc. | 18.23M | ▲ 15.16K |
| Vanguard Capital Management LLC | 12.17M | ▼ 207.47K |
| Vanguard Portfolio Management LLC | 9.41M | ▼ 204.28K |
| State Street Corp | 9.20M | ▼ 70.72K |
| Wellington Management Group Llp | 8.50M | ▲ 3.94M |
| T. Rowe Price Investment Management, Inc. | 6.65M | ▼ 762.06K |
| Jpmorgan Chase & Co | 5.86M | ▼ 85.88K |
| Price T Rowe Associates Inc | 5.68M | ▼ 1.45M |
| Geode Capital Management, LLC | 5.43M | ▼ 25.56K |
| Boston Partners | 5.25M | ▲ 379.09K |
| Morgan Stanley | 3.86M | ▼ 227.95K |
Held by 2,083 ETFs
Biggest fund positions in COR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 11, 26 | Mauch Robert P. | other | 18,292 |
| Nov 11, 26 | Campbell Elizabeth S | other | 4,402 |
| Nov 11, 26 | Boratto Eva C | other | 5,488 |
| Nov 11, 26 | Krikorian Lazarus | other | 3,216 |
| Nov 11, 26 | Verma Pawan | other | 4,231 |
| Nov 11, 26 | Mauch Robert P. | other | 35,589 |
| Nov 12, 26 | Mauch Robert P. | other | 4,682 |
| Nov 12, 26 | Mauch Robert P. | other | 1,927 |
| Nov 11, 26 | Mauch Robert P. | other | 15,478 |
| Nov 12, 26 | Mauch Robert P. | other | 4,682 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our COR coverage
Recent articles, reports, and earnings notes.

Cencora (COR): Specialty Mix Drives Earnings Growth
Cencora is benefiting from specialty-pharma mix shift, GLP-1 volume, and stronger operating income growth across both U.S. and international segments. The stock looks reasonably valued for a defensive healthcare compounder, though leverage remains a key watch item.

Cencora, Inc. (COR) gains on deep earnings beat analysis
Cencora, Inc. (COR) gains after a clean fiscal Q4 beat, but the real story is deeper: specialty-led growth, margin expansion, and strong segment execution. This analysis breaks down the drivers behind the upside, the updated fiscal 2027 outlook, and what the guidance implies for investors.

Cencora, Inc. (COR) gains on earnings beats
Cencora, Inc. (COR) gains 1.2% after reporting earnings beats, lifting shares as investors react to stronger-than-expected results and improved outlook.
Want a deeper read on COR?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Dividend Champion, Contender, And Challenger Highlights: Week Of November 22
seekingalpha.com · Nov 20
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Trustmark Corporation (Nasdaq – TRMK), Maplebear Inc. (Nasdaq – CART), Investcorp Credit Management BDC, Inc. (Nasdaq – ICMB), American Oncology Network, Inc. (OTCQX – AONC)
globenewswire.com · Nov 19
Here's Why You Should Retain Cencora Stock in Your Portfolio for Now
zacks.com · Nov 18
Nike Among 13 Dividend Growth Companies To Announce Annual Dividend Increases In Latter Half Of November
seekingalpha.com · Nov 16
US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus
reuters.com · Nov 13
Cencora, Inc. $COR Shares Bought by Ethic Inc.
defenseworld.net · Nov 12
Dividend Announcements: October 31-November 6, 2026 (Part 2 Of 2)
seekingalpha.com · Nov 8
3 Stocks in Focus That Hiked Dividends Amid Ongoing Market Volatility
zacks.com · Nov 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 19, 2026 · Live quote · Not investment advice